Approval · Notice of Compliance 12389 · 2011
TEVA-MORPHINE SR: Notice of Compliance 12389
Issued June 2, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12389
- Date
- June 2, 2011
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Opioid analgesic
- Canadian reference product
- MS CONTIN (Purdue Pharma)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-MORPHINE SR | 02302764 | Marketed |
| TEVA-MORPHINE SR | 02302772 | Marketed |
| TEVA-MORPHINE SR | 02302780 | Marketed |
| TEVA-MORPHINE SR | 02302799 | Marketed |
| TEVA-MORPHINE SR | 02302802 | Marketed |
Medicinal ingredients
- MORPHINE SULFATE 15 MG per TAB
- MORPHINE SULFATE 30 MG per TAB
- MORPHINE SULFATE 60 MG per TAB
- MORPHINE SULFATE 100 MG per TAB
- MORPHINE SULFATE 200 MG per TAB